

CURRICULUM VITAE

Revised 12/31/2003

LALA MATHERS DUNBAR, MD, Ph.D.

Business Address: Louisiana State University Health Sciences Center
Department of Medicine/Section of Emergency Medicine
1542 Tulane Avenue
New Orleans, LA 70112
(504)903-5657 Phone
(504)903-0306 FAX

EDUCATION:

Undergraduate: George Washington University, Washington, DC
1950-1954 Degree: BS Chemistry, 1954

Graduate: University of Mississippi, Oxford, MS
1954-1955 Graduate Student in Chemistry

1966-1967 University of New Mexico - Holloman AFB Extension, Alamogordo,
NM Graduate Course in Physiology

1967-1972 George Washington University School of Medicine Department of
Biochemistry, Washington, DC
Degrees: MS Biochemistry, 1969 Ph.D. Biochemistry, 1972

Medical Education: George Washington University School of Medicine, Washington, DC
1974-1978 Degree: MD

Post Grad. Medical: Washington Hospital Center, Washington, DC
1978-1981 Internship and residency in Internal Medicine

BOARD CERTIFICATIONS:

Diplomate, National Board of Medical Examiners, 1978
Diplomate, American Board of Internal Medicine, 1981
Diplomate, American Board of Emergency Medicine, 1987
Re-certified in 1997

PROFESSIONAL MEDICAL EXPERIENCE:

- July 98-Present Clinical Professor, Department of Medicine, Section of
Emergency Medicine, Louisiana State University Health Sciences Center
(LSUHSC), New Orleans, LA
- 1991-June 98 Clinical Associate Professor, Department of Medicine, Section of Emergency
Medicine, LSUMC, New Orleans, LA
- 1990-Present Full-time Staff Medical Center of Louisiana (MCLNO), Dept. of Emergency
Medicine
(Contracted through Van Meter & Associates)
- 1990-1991 Clinical Assistant Professor of Medicine, Dept. of Medicine/Emergency
Medicine LSUMC, New Orleans, LA
- 1984-1990 Assistant Professor of Medicine, Dept. of Medicine/Emergency Medicine
LSUMC, New Orleans, LA
- 1985-Present Research Director, Major Emergency Room (MER), MCLNO, New Orleans,
LA
- 1984-Present Attending Staff of Emergency Medicine Residency Program with teaching
responsibilities for House Staff and students rotating on the Emergency
Medicine Service at Charity Hospital (MCLNO), New Orleans, LA
Cost Center Manager for the MER, Charity Hospital, New Orleans, LA
- 1985-1987 Attending Physician with teaching responsibilities for Internal Medicine Ward
teams rotating at Charity Hospital -Endocrine Service, New Orleans, LA
- 1981-1983 Solo private practice in Internal Medicine, Waynesboro, MS
- 1981-1984 Emergency Room Attending Physician at Wayne General Hospital,
Waynesboro, MS
- 1983-1984 Emergency Room Attending Physician at: Rush Foundation Hospital, Meridian,
MS
Jefferson Davis Memorial Hospital, Natchez,
MS
Laurel General Hospital, Laurel, MS

MEDICAL LICENSURE:

State of Louisiana: L # 0674OR, R # 006091 State of Mississippi # 09231

HOSPITAL POSITIONS:

1992-Present Research Review Committee, Charity Hospital/MCLNO, New Orleans, LA
1992-1996 New Orleans Emerg. Med. Seminar Planning Comm., MCLNO, New Orleans,
LA
1990-Present EMS and Critical Care Committees, MCLNO, New Orleans, LA
1993-Present Institutional Grad. Med. Ed. Committee (IGMEC), LSUMC, New Orleans, LA
1990-Present ED Quality Assurance & Peer Review Committees, MCLNO, New Orleans, LA
1985-Present Director, MER, MCLNO, New Orleans, LA
1985-Present Cost Center Manager, MER, MCLNO, New Orleans, LA
1984-Present Visiting Physician, Charity Hospital/MCLNO, New Orleans, LA
1990-1991 Committee to Revise Consultation Policy, MCLNO, New Orleans, LA
1991-Present Director of Research for Section of Emerg. Medicine, MCLNO, New Orleans, LA
1986-1988 AIDS Advisory Committee, MCLNO, New Orleans, LA
1982-1984 Utilization Review Committee, Wayne General Hospital, Waynesboro, MS
Chairman, Library Committee, Wayne General Hospital, Waynesboro, MS
Director, Continuing Med. Ed. for Staff -Wayne General Hospital, Waynesboro,
MS

ACADEMIC APPOINTMENTS:

1998-Present Clinical Professor of Medicine, LSUMC, New Orleans
1991-1998 Clinical Associate Professor of Medicine, LSUMC, New Orleans, LA
1990-1991 Clinical Assistant Professor of Medicine, LSUMC, New Orleans, LA
1984-1990 Assistant Professor of Medicine, LSUMC, New Orleans, LA
1973-1974 Research Associate in Biochemistry, George Washington Univ., Washington, DC
1972-1973 Post-Doctoral Fellow in Biochemistry, George Washington Univ., Washington,
DC
1969-1972 Graduate Teaching Fellow in Biochemistry, George Washington Univ.,
Washington, DC

PROFESSIONAL SOCIETY MEMBERSHIPS:

American College of Physicians (ACP) - Fellow, 1987
American Association of Women Emergency Physicians (AAWEP)
 Nominated by AAWEP for the ACEP Annual Research Award 1996, 1998
American College of Emergency Physicians (ACEP) - Fellow, 1989, re-certified in 1997
Member of Section for Observation Medicine, Disaster Medicine;
 Member Louisiana Chapter: Board Member and Alternate Counselor
 Louisiana Planning Committee
 Research Member: Educational Meetings Planning Committee, 1993-1996
Alpha Omega Alpha (AOA) - Medical Honor Society
Sigma XI - Scientific Research Society
Society for Academics in Emergency Medicine (SAEM) - 1991
 Member Research Committee, 1991-1994; Managed Care Interest Group;
 Observation Medicine Interest Group; Research Directors Special Interest Group;
American Federation for Clinical Research (AFCR)
Orleans Parish Medical Society
Louisiana State Medical Society
American Society for Hypertension (ASH)
American Society for Microbiology
European Respiratory Society

EDUCATIONAL PROGRAMS AND INVITED LECTURES:

Grand Rounds, Department of Surgery, University of Mississippi 1972
 Lecture title: Polyunsaturated Fatty Acid Metabolism and Medical Implications of Prostaglandins.

Grand Rounds, Department of Medicine, LSUMC
 Lecture titles: Life and Death - What It Takes
 State of Fluid Overload
 Coma and Altered States of Consciousness
 The Admission Decision: Triage Management of ER Patients
 Management of Congestive Heart Failure in the ER
 Plant Poisoning: Cocaine Toxicity
 Hypertension in the Emergency Department-Management of Urgencies
 &
 Emergencies
 Chest Pain in the Emergency Department-Who's having a Heart
 Attack?
 Pneumonia - Focus on Pathogens

Symposium on Management of Edema; Annual Scientific Assembly of the American College of Emergency Physicians, Atlanta, GA, September 14, 1986 Lecture title: Management of Edema in the ER

The LSU-New Orleans Emergency Medicine Seminar, New Orleans, LA:

April 1987 Lecture Title: Thrombolytic Therapy in Acute Myocardial Infarction
April 1988 Lecture Title: Update in Toxicology: Tricyclic and Dioxin Toxicity
June 1990 Lecture Title: Management of Congestive Heart Failure in the ED
June 1994 Lecture Title: Chest Pain in the ED - Enzyme Markers to Assist in the
Diagnosis of MI
June 1995 Lecture Title: Community-Acquired Pneumonia

Home Health Care Symposium, Snowbird, UT, January 1989
Lecture Title: Triage Decisions in the ER - Who Should Be Admitted?

Symposium on Managing, Infections in the ER, La Costa, CA, April 1989
Lecture title: Triage Decisions for Infected Patients in the ER, New Trends in Health Care

Symposium on Congestive Heart Failure, Annual Scientific Assembly of the American
College of Emergency Medicine Physicians, Washington, DC, 1989 Lecture Title: Congestive
Heart Failure in the ER

Symposium on Oral Antibiotic Usage in the 1990's Lecture Title: Triage Decisions for the
Infected

Patient in the Emergency Department. Sites - Seattle, Boston, Pittsburgh - Grand Rounds
Emergency Management of Congestive Heart Failure: Staff Grand Rounds, Palms of Pasadena
Hospital, St. Petersburg, FL, May 1991

SAEM Annual Meeting, Washington, DC, May 1991 Lecture Title: A Comparison of
Intravenous Fenoldopam vs. Sodium Nitroprusside in the Management of Hypertensive
Urgencies and Emergencies.

North Broward Medical Center, Pomona Beach, FL, May 1991
Lecture Title: Emergency Management of Congestive Heart Failure: Staff and ED

Lectures To LSU Freshmen Medical School Class:
Coma and Altered States of Consciousness
Medico-Legal Aspects of Emergency Care

Graff, LG, Dunbar, LM, Maldonado, AR, et al., Effects of Residents on Emergency Physician
Workload,
Industry and Pharmaceutical Research Session at the SAEM Annual Meeting, May 1993.

Dunbar, LM, et al, Analysis of a Severity of Illness Index Designed to Assist in the
Assessment of Patients
with CHF. ACEP Research Forum poster presentation, San Francisco, CA, March 1994

SAEM Annual Meeting, Washington, DC, May, 1994
Lecture Title: A Curriculum for Teaching Residents Research.

SAEM Annual Meeting, San Antonio, TX, May 1995. Poster Title: The Bacterial Pathogens of Community Acquired Pneumonia Coexistence of Typical and Atypical.

Tulane Emergency Medicine Interest Group, November 27, 1995

Discussant for the American College of Emergency Physicians Research Forum, Cincinnati, OH, February 24-25, 1996.

LSU/Emergency Medicine Board Review Course: Sept. 1996 Lectures on Pneumonia and Endocrine Emergencies; Sept. 1997: Lectures on Pneumonia and TB; Sept. 1998: Lectures on Pneumonia and TB.

Tulane Emergency Medicine Interest Group, November 22, 1996

Moran, GJ, Talan DA, Mower, W, et al (includes Dunbar, LM as IDnet investigator), Emergency Department Sentinel Surveillance for Animal Contacts and Rabies Prophylaxis. VII Annual International Meeting on Research Advances & Rabies Control in the Americas, Atlanta, GA. December 13, 1996.

SAEM Annual Meeting, Washington, DC, May, 1997
Breakout session Faculty at the Research Director's Workshop.

Dunbar, LM, et al, Aggressive ED Management of DKA: Impact on Disposition and Outcome. APCR/Southern Societies Section poster presentation, New Orleans, LA, February 5, 1997

Moran, GJ, Talan DA, Mower, W, et al (includes Dunbar, LM as IDnet investigator), Neurocysticercosis Presenting as Seizures in the Emergency Department. CDC/NIH Workshop on Neurocysticercosis: An Emerging Public Health Problem, Current State of the Art Diagnostic and Management Perspectives, Boston, MA. April 1997.

Moran, GJ, Talan DA, Mower, W, et al (includes Dunbar, LM as IDnet investigator), Sentinel Surveillance for Animal Contacts and Rabies Prophylaxis. SAEM Annual Meeting, Washington, DC. May 20, 1997.

Dunbar, LM, et al, Analysis of Blood Pressure Prior to Intervention in Hypertensive Emergencies and Urgencies. ACEP Research Forum poster presentation, San Francisco, CA, October 1997.

Roberts, J, Dunbar, LM, et al, Serious Childhood Anemia - A Continuing Public Health Problem. ACEP

Research Forum poster presentation, San Francisco, CA, October 1997.

Dunbar, LM, et al, ED Management of Hypertensive Emergencies with Fenoldopam, SAEM Annual Meeting, Chicago, IL, 1998.

Dunbar, LM, et al, ED Management of Hypertensive Emergencies with Fenoldopam, SAEM Regional Meeting, New Orleans, LA, 1998.

Dunbar, LM, Discussant, Oral Session and Poster Presentations, SAEM Annual Meeting, Chicago IL, 1998

Dunbar, LM, Lecture: “ How to be a Successful Clinical Trial Investigator”, SAEM Annual Meeting, Chicago IL, 1998.

Dunbar, LM, “Current Issues in Antibiotic Usage in the ED”, Grand Rounds Medical College of VA, Richmond, VA, Feb. 3, 1999.

Dunbar, LM, “Current Issues in Treatment of Pneumonia”, Residents Conference Southeastern VA Medical School, Virginia Beach, VA, Feb. 4, 1999.

Dunbar, LM, “Current Issues in Antibiotic Usage in the ED”, Residents Conference Naval Medical Center, Norfolk, VA, Feb. 4, 1999.

Dunbar, LM, Member of the Ortho McNeil Speaker’s Bureau, 1999.

Dunbar, LM, Member of the Roche Speaker’s Bureau, 1999.

Dunbar, LM, “Community Acquired Pneumonia Current Concrens in Therapy”, Pfizer lecture, January 23, 2000.

Dunbar, L, Hagberg, L, Rangaraju, M and Leroy, B, Seven to 10Day Therapy with Telithromycin the First Ketolide Antimicrobial is Effective in Community Acquired Pneumonia Caused by Atypical and Intracellular Pathogens, ICAAC 2000.

Dunbar, LM, Jubelin, BCL and Sibley, DET, Co-Existence of Pathogens in Community Acquired Pneumonia (CAP), ICAAC 2000.

Jubelin, B, Hendifar, A, Sibley, D, and Dunbar, L, Hyponatremia in Community Acquired Pneumonia: Is It Truly a Marker for Legionella?, ACEP Research Forum, Las Vegas, NV, October 2000.

Dunbar, L, “Chest Pain in the ED: Who’s Having a Heart Attack?”, January 22, 2001.

Dunbar, L, “Triage and Treatment of Respiratory Infections in the Emergency Department”, Feb. 28, 2001.

Dunbar, L, Jubelin, B, Gohil, R, and Sibley, D, Aggressive Management of Diabetic Ketoacidosis: Time Course for Correction of Metabolic Abnormalities, ACEP Research Forum, Seattle, WA, October 2002.

Vrooman, P, Dunbar, L, and Sigillitto, R, Efficacy Comparisons Between the Ketolide Telithromycin and Clarithromycin, Amoxicillin, and Trovafloxacin in Patients With Community Acquired Pneumonia of Differing Severities, ACEP Research Forum, Seattle, WA, October 2002.

Dunbar, L, “Current Issues in Management of Community Acquired Pneumonia”, Emergency Medicine Symposium, Hot Springs, AR, March 27, 2003.

Dunbar, L, “New Insights and New Options in the Management of Congestive Heart Failure”, Emergency Medicine Symposium, Hot Springs, AR, March 27, 2003.

Dunbar, L, Sibley, D, Waldren, A, and the EMERGENCY Idnet Study Group, Pneumococcal Resistance to Penicillin in Community Acquired Pneumonia, Regional SAEM meeting, Jacksonville, FL, April 2003

Dunbar, L, Khashab, M, Tennenberg, A, and Khan, J, Efficacy of High Dose, Short Course, of Levofloxacin vs Standard 10-Day Therapy for Treatment of Community Acquired Pneumonia (CAP) Caused by Atypical Pathogens, Regional SAEM meeting, Jacksonville, FL, April 2003 and SAEM Annual Assembly, Boston, MA May, 2003

Dunbar, L, Talan, D, Sibley, D, and the EMERGENCY Idnet Research Study Group. Antimicrobial Resistance of Streptococcus pneumoniae Recovered From Patients With Lower Respiratory Tract Infections in the United States During 1997-2000, 2nd Mediterranean Emergency Medicine Congress, Barcelona, Spain, September 17, 2003.

Dunbar, L, et al, Telithromycin Displays High Clinical Efficacy in Outpatients with Mild to Moderate Community Acquired Pneumonia Caused by Atypical/Intracellular Pathogens, European Respiratory Society’s Annual Congress, Vienna, Austria, September 28, 2003.

NON-MEDICAL ACTIVITIES:

- 1952 - 1954 Cheerleader, George Washington Univ., Washington, DC, Kappa Kappa Gamma Fraternity.
- 1956 - 1983 Wife of US Air Force test pilot and Olympic gold medallist.
- 1976 - 1978 Selected with other Air Force wives to meet regularly with the wife of the USAF Chief of Staff to consider problems of Air Force family life.
- Red Cross Volunteer

EMPLOYMENT PRIOR TO MD DEGREE:

George Washington University School of Medicine, Washington, DC:

1973 - 1975 Research Associate
1972 - 1973 Post-doctoral Fellow
1969 - 1972 Graduate Teaching Fellow
1968 - 1969 Student Research Assistant

United High School, Laredo, TX:

1973 - 1973 Teacher of Advanced Biology and Chemistry courses

Aeromed Research Lab, Holloman AFB, New Mexico:

1966 - June 1967 Clinical chemist FDA supported study of Chloramphenicol use in chimpanzees.

Department of the Navy, Naval Engineering Experimental Lab, Annapolis, MD:

1956 - 1956 Chemist

National Institutes of Health - National Heart Association, Bethesda, MD:

1955 - 1955 Chemist in lab of Dr. James O. Davis studying action of Aldosterone

University of Mississippi, Department of Chemistry, Oxford, MS:

1954-1955 Graduate Teaching Assistant

Department of Recreation, Arlington, VA:

Summers, 1952 - 1954 Playground Director

Department of the Army, Pentagon, Washington, DC:

Summer, 1951 Clerk Typist

SUPPORTED RESEARCH:

1989 Smith, Kline and French. A Multinational, Multicenter, Open-Label, Comparison of Intravenous

"Corlopam" vs Sodium Nitroprusside In Patients with Severe Hypertension.
\$112,000.

Principal Investigator. Study completed.

1989 Hoffman-LaRoche Laboratories, Inc. Aggressive Management of Congestive Heart Failure in the

Emergency Room Setting Using Bumetanide. \$55,320. Principal Investigator.
Study completed.
(Results in preparation for publication).

1990 Hoechst-Roussel. A Multicenter, Observer-Blind Study of the Safety, Efficacy and Tolerance of Cefpirome (HR 810) Versus Ceftriaxone in the Treatment of Patients with Skin and Soft Tissue Infections. \$1200 per patient x 18 patients. Co-Investigator. Study completed July 1990.

1990 Anaquest. An Open-Label Study of Parenteral Nalmefene in Narcotic and Mixed Drug Overdose. \$20,850. Principal Investigator. Study completed May, 1990.

1990 Pfizer. Comparison of Ampicillin/Sulbactam (Unasyn) Versus Bactrim in Management of Pyelonephritis. Co-Investigator. Study Completed 1992.

1991 Syntex. Evaluation of the efficacy and safety of Nicardipine in the Treatment of Urgent Hypertension. \$32,211. Principal Investigator. Study completed 1992.

1992 Hoffmann-La Roche. Treatment of Community-Acquired Pneumonia of Mild to Moderate Severity with Fleroxacin vs Ciprofloxacin. \$35,240. Principal Investigator. Study completed 1993.

1992 Merck Sharp Dohme. A comparison of Primaxin vs. Timentin for treatment of skin and soft-tissue infections. Co-Investigator. Study Completed 1993.

1994 R.W. Johnson - A Comparison of Safety and Efficacy of IV Levofloxacin vs. IV Ceftriaxone and/or Oral Ceftin in the Treatment of Community Acquired Pneumonia. \$95,582. Principal Investigator. Study completed January 1995.

1995 Pfizer, Inc. - A Randomized, Multicenter, Investigator-Blind Trial Comparing Intravenous CP 116,517 Followed by Oral CP99,219 with Intravenous Ciprofloxacin and Ampicillin Followed by Oral Ciprofloxacin and Amoxicillin for the Treatment of Community Acquired Pneumonia. \$6,812 - 12 Patients. Principal Investigator. Study completed April 1996.

1995 Otsuka America, Inc. Double-Blind Comparative Study of the Efficacy and Safety of Orally Administered OPC-17116 and Clarithromycin in the Treatment of

Patients with Community Acquired Pneumonia. \$39,450. Principal Investigator. Study completed May 1996.

1996 Pfizer Inc. A Randomized, Multicenter, Double Blind, Double-Dummy Trial Comparing CP99,219 with Amoxicillin and Optional Erythromycin for the Treatment of Community-Acquired Pneumonia. \$5,550. Principal Investigator. Study completed May, 1996.

1996 Neurex, Inc. A Multicenter, Randomized, Double Blind with Respect to Dose, Evaluation of Intravenous Fenoldopam in Patients with a Hypertensive Emergency. \$115,043. Principal Investigator. Study completed January 1997.

1996 Cambridge NeuroScience. Efficacy and Safe of CERESTAT® (aptiganel HCl) as a Neuroprotective Following Severe Traumatic Brain Injury. Co-Principal Investigator. \$1500. Study closed July 1996.

1996 Pfizer. Intravenous CP 116,517 vs. Zosyn for Treatment of Complicated Skin and Soft Tissue Infections Co-Investigator. Study completed.

1996 Pfizer. Oral CP 99,219 vs. Vantin for Treatment of Uncomplicated Infections Requiring Antibiotic Therapy. Co-Investigator. Study completed.

1996 Center for Disease Control. A National Emergency Medicine Sentinel Network for Surveillance of Emerging Infections. \$42,600. Principal Investigator. Study active.

1996 R.W. Johnson - A Noncomparative Multicenter Study to Evaluate the Safety and Efficacy of Levofloxacin 500mg Once-Daily in the Treatment of Community Acquired Pneumonia in Adults. \$117,700. Principal Investigator. Study completed.

1997 Pfizer, Inc. - A Randomized, Double-Blind, Multicenter, Trial Comparing 10 Days of Oral Therapy with Trovafloxacin CP 99,219 (200mg Once-Daily) and 14 Days of Oral Clarithromycin (500mg, BID) for the Treatment of Acute Sinusitis. \$2,448 x 8 Patients. Principal Investigator. Study completed.

1997 Proctor & Gamble, Inc. A Multi-Center, Double-Blind, Placebo-Controlled Parallel Design Clinical Trial to Assess the Efficacy and Safety of 50mg, 100mg, and 125mg of Azimilide Dihydrochloride for the Prophylactic Treatment of Symptomatic Atrial Fibrillation/Flutter and/or Symptomatic Paroxysmal Supraventricular Tachycardia. \$2,500. Principal Investigator. Study completed March 1997.

1997 Proctor & Gamble, Inc. A Multi-Center, Open-Label Clinical Trial to Assess the Long-Term Safety of 100mg of Azimilide Dihydrochloride in Patients with Atrial

Fibrillation/Flutter and/or Paroxysmal Supraventricular Tachycardia. \$2,500.
Principal Investigator. Study completed March 1997.

- 1997 Neurex, Inc/Parke-Davis. A Double-Blind, Randomized, Placebo-Controlled Study of CI-1009 in Patients with a Severe Head Injury. \$26,500. Co-Principal Investigator. Study closed July 1998.
- 1997 Bayer, Inc. A Prospective, Randomized, Comparative Study of Ciprofloxacin and Clarithromycin for the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Principal Investigator. \$1650. Study completed 1997.
- 1997 Ortho-McNeil Pharmaceutical. Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin vs. Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin/Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults \$71,100. Principal Investigator. Study completed 1998.
- 1997 ViroPharma, Inc. A Double-Blind, Placebo-Controlled Trial of VP63843 in the Treatment of Enteroviral Meningitis in Adolescents and Adults. \$15,000. Principal Investigator. Study completed 1998.
- 1997 Searle, Inc. Clinical Protocol for Dose Ranging Study of Eplerenone vs. Placebo in Patients with Symptomatic Heart Failure. \$27,106.26. Principal Investigator. Study completed June 1998.
- 1998 HMR. A Double-Blind, Multicenter, Randomized, Active Controlled, two-arm, Parallel Group, Comparative study of the Efficacy and Safety of Oral HMR 3647 vs Oral Clarythromycin in the Treatment of CAP in Adults. \$114,500. Principal Investigator. Study Completed 1999.
- 1998 Merck. A prospective, Multicenter, Double Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of MK-0826 versus Ceftriaxone Sodium in the Treatment of CAP in Adults. \$100,800. Principal Investigator. Study completed 2000.
- 1998 ViroPharma, Inc. A Double-Blind, Placebo-Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Adolescents and Adults. \$4,500. Principal Investigator. Study closed.
- 1999 Innovex, Inc. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Efficacy Based on the Time to Treatment of Influenza Infection with the Neuraminidase Inhibitor Ro64-0796. \$6,510. Principal Investigator. Study completed 1999.

- 1999 Integrated Infusion Services. Tetanus Immunity and Wound Prophylaxis Among At-Risk Emergency Department Patients (COWS). \$58,125. Principal Investigator. Study completed 2000.
- 1999 Abbott Laboratories. Comparison of the Safety and Efficacy of Clarithromycin IR (250 mg BID) to Levofloxacin (500 mg QD) for the Treatment of Community-Acquired Pneumonia. \$13,000. Principal Investigator. Study completed 2000.
- 1999 HMR. An Open-Label, Multicenter, Multinational Uncontrolled Study of the Efficacy and Safety of Oral HMR3647 (800 mg Once Daily) Given for 7 Days in the Treatment of Community-Acquired Pneumonia in Adults. 20 subjects. Principal Investigator. HMR 3647/3010. \$74,000. Study Completed 2000.
- 2000 SmithKline Beecham
An open, non-comparative, multicenter study to assess the efficacy and safety of oral augemntin SR 2000 mg /125 mg twice daily for 7 days for the treatment of bacterial community acquired pneumonia in adults. BRL-025000/547 \$69,953. Study Active
- 2000 SmithKline Beecham
A randomized, double-blind, double-dummy, multicenter, parallel group study to assess the effectiveness and health economic impact of oral Factive (gemifloxacin), 320mg once daily for 5 days versus oral clarithromycin 500mg twice daily for 7 days for the treatment of acute exacerbation of chronic bronchitis (AECB) . SB – 265805/112. \$12,312. Study Completed 2000.
- 2000 Alexion/Procter and Gamble
Comply: complement inhibition in myocardial infarction treated with thrombolytics. A randomized, double-blind, placebo-controlled study of two intravenous dosing regimen of H5g1.1-scFb in patients with acute myocardial infarction undergoing thrombolytic reperfusion therapy. Comply : 1999052 Study closed by Dr. Martinez September 2001.
- 2000 Aventis
Traumanox DVT a randomized double blind trial comparing the efficacy and safety of enoxaperin 30 mg q 12 hrs and enoxaperin 40 mg q d with Sodium Heparin 5000 IU q 12 hrs, all administered sub-cutaneously for a maximum of 14 days, as prophylaxis against venous thromboembolism after a major trauma. Protocol No.: RP5463-314 Study closed 2001.
- 2001 Aventis
HMR 3647. An Open-Label, Multicenter, Multinational Uncontrolled Study of the Efficacy and Safety of 7 Days of Oral telithromycin (HMR3647 - 800 mg Once Daily) in the Treatment of Community-Acquired Pneumonia Due to *Streptococcus pneumoniae* in Adolescent and Adults. Protocol No.: HMR 3647/3012. \$60,000. Study Completed August 2002.

- 2001 Scios Prospective Randomized Outcomes Study of Acutely Decompensated CHF Treated Initially in Outpatients with Natrecor[®]; THE PROACTION TRIAL. Protocol No: 704.301. \$80,000. Study terminated.
- 2001 Ortho McNeil Pharmaceuticals. Multicenter, double blind, randomized study to compare the safety and efficacy of levofloxacin 750 mg once daily for five days vs levofloxacin 500 mg once daily for 10 days in the treatment of mild to severe community-acquired pneumonia in adults. Protocol CAPSS 150. \$4,800. Study completed May 2002.
- 2001 Ortho McNeil Pharmaceuticals Multicenter, Open Label, Non-Comparative Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg once a day for 5 days in the Treatment of Mild To Severe Community-Acquired Pneumonia in Adults. Protocol CAPSS-171. Study completed May 2002.
- 2002 Bristol-Myers Squibb. An Open Label, Non-Comparative, Multi-National Study of BMS-284756 in the Treatment of Community Acquired Pneumonia Caused by Penicillin Resistant *Streptococcus pneumoniae*. Protocol No.: AI464-073. \$56,250. Study completed April 2003.
- 2003 Aventis Pharmaceuticals. Insulin glargine [rDNA origin] injection (Lantus[®]) vs. pioglitazone (Actos[®]) as Add-on Therapy in patients failing Monotherapy with sulfonylurea or metformin (Glucophage[®]): A randomized, open, parallel study. Protocol No.: HOE901/4020. \$33,565. Study Active.
- 2003 Bayer Corporation, A Study of Avelox for Treatment of Elderly Patients with Community Acquired Pneumonia. (The SAFE CAP Study). Protocol No: 10872. Study Active.
- 2003 Aventis Pharmaceuticals, An Observational, Non-Interventional, Retrospective, International Study to Investigate Factors Responsible for Hospitalization, and Subsequent Outcomes, of Patients with Community Acquired Pneumonia (CAP) Protocol No.: HMR3647A/9003. \$10,000. Study completed August 2003.
- 2003 MARC-14 Fourteenth Multicenter Airway Research Collaboration. \$2,000. Study completed 4/2003.
- 2003 Ortho-McNeil Pharmaceuticals. Comparison of the Efficacy and Safety of Tramadol HCl/Acetaminophen versus Hydrocodone Bitartrate/Acetaminophen versus Placebo in Subjects with Acute Musculoskeletal Pain. Protocol CAPSS-216. Study Active.
- 2003 Theravance, Inc. Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous ARBELIC versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections. .Protocol No.: I6424-202a. Study completed 12/2003.

2003 Pfizer, Inc. A Multicenter, Randomised, Double-Blind, Double-Dummy Comparative trial of Azithromycin SR Versus Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults. Protocol A0661075. Study Active.

Ongoing We are members of the **EMERGENCY IDNet** group, subsidized partially by the CDC, to collect epidemiologic data gathering to tract specific emerging infectious diseases:

OTHER CURRENT RESEARCH INTERESTS:

Metabolism of Omega-3 and Omega-6 Fatty Acids in Cultured Cells: Research in Collaboration with Nicholas, Bazan, MD, Ph.D., LSU Department of Biochemistry and Ophthalmology.

Evaluation of New Biochemical Markers Troponin T and Troponin I. Additionally Measured in Patients with Cardiac Related Disorders Presently Being Diagnosed and Treated by Traditional Laboratory Tests such as Aggressive ED Management of DKA: Impact on Disposition and Outcome (Retrospective Study). Principle Investigator. Study completed January 1996.

Aggressive ED Management of DKA (Prospective Study). Principle Investigator. Study in progress.

Aggressive Management of Hypertension in the ED (Prospective Study). Principle Investigator. Study in progress.

Management of Hyperglycemia in the ED (Prospective Study). Principle Investigator. Study in progress.

Hyponatremia in Community Acquired Pneumonia

Co-existence of Typical and Atypical Pathogens in Community Acquired Pneumonia

BOOK CHAPTERS:

Dunbar, LM, Congestive Heart Failure in: Observation Medicine, 1st Edition Louis G. Graff NM (Editor) Andover Medical Publishers, Inc., 1993.

Dunbar, LM, Regulation of Blood Pressure in: Emergency Medicine, 2nd Edition, Harold May (Editor). Little, Brown & Co., Boston, 1992

Dunbar, LM. Diabetic Emergencies in Critical Decisions In Emergency Medicine. CME Lessons. Accepted for Publication.

BIBLIOGRAPHY OF PUBLICATIONS:

Dunbar, LM and Bailey, J Martyn, Growth of Ascites Tumors Deficient in Essential Fatty Acids, Fed. Prod. 28: p 557, (1969).

Bailey, JM and Dunbar, LM, Lipid Metabolism in Cultured Cells: Growth of Tumor Cells Deficient in Essential Fatty Acids, Cancer Research, 31, pp. 91-97, (1971).

Bailey, JM, Howard, BV, Dunbar, LM and Tilhnan, SF, Control of Lipid Metabolism in Cultured Cells, Lipids, Z, pp. 125-134, (1972).

Dunbar, LM and Bailey, JM, Essential Fatty Acid Requirements of Tumor Cells, Fed. Proc., 31, p 674, (1972).

Bailey, JM and Dunbar, LM, Essential Fatty Acid Requirements of Cells in Tissue Culture: A Review, Exp. and Molecular Path. 1. 83 pp 142-161, (1973).

Dunbar, LM and Bailey, JM, Enzyme Deletions and Essential Fatty Acid Metabolism in Cultured Cells, J. Biol. Chem., 250, pp. 1152-1153 (1975).

Dunbar, LM and Bailey, JM, Conversion of Essential Fatty Acids to Prostaglandin Precursors by Cultured Cells, Fed., Proc., 33, (1974).

Master's Thesis: Growth and Properties of Ascites Tumor Cells Deficient in Essential Fatty Acids, George Washington University, February 1969.

Ph.D Dissertation: Growth, Fatty Acid Metabolism, Respiration and Morphology of Mammalian Cells Cultured in the Absence of Essential Fatty Acids, George Wash. Univ., June 1972.

Dunbar, LM, Management of Edema in Emergency situations. Proceedings of a Symposium2 Excerpta Medica, December 1986.

Dunbar, LM, Fluid and Electrolyte Disorders: The Diagnostic Challenge, Acute Care Therapeutics, Pracon Inc. Pub., Vol 3, 83, p 4, 1988.

Dunbar, LM and Knoblauch, G, Severe Hyponatremia and Metabolic Alkalosis: A Case Report, Acute Care Therapeutics, ibid. pp 12-13, 1988.

Dunbar, LM, Management of Congestive Heart Failure in the Emergency Room, Proceedings of a Symposium. Hospital Practice, January 1990.

Dunbar, LM, Gregg, K and Simmons, S. A Comparison of IV Fenoldopam vs. Sodium Nitroprusside in the Management of Hypertensive Urgencies and Emergencies, *Annals Emergency Med.*, 1991 Vol. 20, # 4, p 483.

Dunbar, LM, Dyer, TW, Congestive heart failure patients: Admit or discharge? A prospective study of observation unit care 101 patients. *Clinical Research*, 1991; 39(4): 828A.

Dunbar, LM, Emergency Management of Urgent Hypertension with Oral Nifedipine, *Clinical Research*, Volume 40, Number 4, December 1992.

Graff, Louis, Dunbar, LM, et. al., Observation Medicine: An Annotated Bibliography. *Ann J Emerg Med* 1992;10; 84-93.

Graff, LG, Dunbar, LM, et. al., Observation Medicine Curriculum. *Ann Emerg Med* 1992;21: 963-966

Dunbar, LM, Thompson, H, and Maldonado, AR, Analysis of Severity of Illness Index for Assessment of Congestive Heart Failure. abstract - *Acad. Emergency Medicine*, January 1994.

Dunbar, LM, et al, Analysis of a Severity of Illness Index Designed to Assist in the Assessment of Patients with CBF. abstract - *Annals of Emergency Medicine*, March 1994

Dunbar, LM, Martin, DH, Giddens, J and Sibley, DET, The Bacterial Pathogens of Community Acquired Pneumonia: Coexistence of Typical and Atypical. abstract - *Acad. Emergency Medicine*, March/April 1995.

Panacek, EA, Bednarczyk, EM, Dunbar, LM, Foulke, GE, & Holclaw, TL, Randomized, Prospective Trial of Fenoldopam vs. Sodium Nitroprusside in the Treatment of Acute Severe Hypertension. *Acad. Emerg. Med.*, 1995, Vol 12, Issue 11, 959-965.

File, TM, Segreti, J, Dunbar, L, Player, R, Kohler, R & Williams, R, A Multicenter, Randomized Study Comparing the Efficacy and Safety of IV/PO Levofloxacin (LVFX) vs. Ceftriaxone/Cefuroxime axetil (cc) in the Treatment of Adults with Community Acquired Pneumonia (CAP). 36th Annual ICAAC Conference abstract, New Orleans, LA, September, 1996.

Moran, GJ, Talan DA, Mower, W, et al (includes Dunbar, LM as IDnet investigator), Emergency Department System Surveillance for Animal Contact for Rabies Prophylaxis. *Acad. Emerg. Med.*, May 1997, Vol 4, Issue 5, 386.

File, TM, Segreti, J, Dunbar, L, Player, R, Kohler, R & Williams, R, A Multicenter, Randomized Study Comparing the Efficacy and Safety of IV/PO Levofloxacin (LVFX) vs. Ceftriaxone/Cefuroxime axetil (cc) in the Treatment of Adults with Community Acquired Pneumonia (CAP). *Antimicrobial Agents and Chemotherapy*, September, 1997.

Tumlin, Dunbar, LM, et al, Fenoldopam, a Dopamine Agonist, for Hypertensive Emergencies: A Multicenter Randomized Trial. *Acad. Emerg. Med.*, June 2000, Vol 7(6), 653-662.

Talan, D.A., et al (includes Dunbar, LM as IDnet investigator), Etiology of Bloody Diarrhea Among Patients Presenting to United States Emergency Departments: Prevalence of E. coli 0157:H7 and Other Enteropathogens. Accepted for publication, *JAMA* 2000.

Dunbar, L, M. , Jubelin, B.C. and Sibley, D. Co-existence of Pathogens in Community Acquired Pneumonia (CAP). 40th Annual ICAAC Conference abstract, Toronto, Ont., Canada, September, 2000.

Mower, WR, Biros, M, Talan, D, Moran, G, Ong, S for the EMERGENCY IDnet (including Dunbar, LM). Selective Tomographic Imaging of Patients with New-Onset Seizure Disorders. *Acad Emerg Med.*, Jan 2002, Vol 9(1), 43-47.

Ong S, Talan DA, Moran GJ, Mower W, Newdow M, Tsang VCW, Pinner RW, and the EMERGENCY ID Net Study Group (including Dunbar, LM). Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. *Emerg Infect Dis* ; 8(6): 608-613, June 2002.

Dunbar, LM. Current Issues in the Management of Bacterial Respiratory Tract Disease: The Challenge of Antibacterial Resistance. *The Amer J of the Med Sci*, September 2003, Vol 326, Issue 3.

Dunbar, LM, Carbon C, Rensburg, D, Tellier, G, Rangaraju, M and Nasrat, R. Efficacy of Telithromycin in Community Acquired Pneumonia Caused by Atypical and Intracellular Pathogens. *Infect Dis Clin Pract*, Submitted July 2003.

Dunbar, L, Hassman, J, and Tellier, G. Efficacy and Tolerability of Once Daily Oral Therapy with Telithromycin Compared with Clarithromycin for the Treatment of Community Acquired Pneumonia in Adults. Accepted for publication early 2004 by *Excerpta Medica*

Dunbar, L, Talan, D and Sibley, D for the EMERGENCY IDnet Investigators. Antimicrobial Resistance of *Streptococcus pneumoniae* Recovered From Patients with Lower Respiratory Tract Infections in the United States During 1997-2000. *J Manuscript in preparation*

Fogarty CM, Greenberg RN, Dunbar L, Player R, Marrie TJ, Kojak CM, Morgan N, Williams RR. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant *Streptococcus pneumoniae*: integrated results from four open-label, multicenter, Phase III clinical trials. *Clin Ther.* 23(3) 425-39, 2001 Mar.

Hagberg L, Carbon C, van Rensburg DJ, Fogarty, Dunbar L, and Pullman J, Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. *Respiratory Medicine*. Vol 97 (2003) 625-633

Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB, High-dose, Short-course Levofloxacin for Community-acquired Pneumonia: A New Treatment Paradigm. *CID* 2003;37:752-60